Affimed GmbH

169 articles about Affimed GmbH

• Affimed Announces Acceptance of Abstracts at the 17th International Conference on Malignant Lymphoma (17-ICML)

  6/9/2023

  Affimed N.V. announced that two abstracts have been accepted for presentation at the 17th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland on June 13-17, 2023.

• Affimed Presents AFM24 Monotherapy Data in Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology and Provides Strategic Update on AFM24 Development Plan

  6/3/2023

  Affimed N.V. announced the presentation at the American Society of Clinical Oncology Annual Meeting of safety and efficacy data from the EGFR mutant NSCLC expansion cohort of its ongoing phase 1/2 study investigating innate cell engager AFM24 as monotherapy.

• Affimed to Present at the 2023 Jefferies Healthcare Conference

  5/30/2023

  Affimed N.V. announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2023 Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. Eastern Daylight Time / 14:30 Central European Time.

• Affimed Announces Publication of AFM24 Clinical Abstracts for the Annual Meeting of the American Society of Clinical Oncology

  5/25/2023

  Affimed N.V. announced the publication of two abstracts with its innate cell engager AFM24 in advance of the American Society of Clinical Oncology Annual Meeting, taking place on June 2 - 6, 2023 in Chicago, IL.

• Affimed Reports First Quarter 2023 Financial Results and Highlights Operational Progress

  5/23/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results and provided an update on clinical and corporate progress for the first quarter of 2023.

• Affimed Announces IND Clearance for a Phase 2 Clinical Trial Investigating AFM13 and AB-101 Combination Therapy

  5/23/2023

  Affimed N.V. announced that the U.S. Food and Drug Administration has cleared its IND application for the combination of AFM13, its first-in-class tetravalent bispecific innate cell engager and AB-101, Artiva Biotherapeutics Inc.’s clinical-stage, cryopreserved, off-the shelf, non-genetically modified, allogeneic cord blood-derived natural killer cells to initiate the clinical trial, AFM13-203.

• Affimed Announces Annual General Meeting of Shareholders - May 22, 2023

  5/22/2023

  Affimed N.V. announced that its 2023 Annual General Meeting of Shareholders will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.

• Affimed to Report First Quarter 2023 Financial Results & Corporate Update on May 23, 2023

  5/16/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023.

• Affimed Announces Abstracts at the Annual Meeting of the European Hematology Association

  5/11/2023

  Affimed N.V. announced that two abstracts have been accepted to EHA2023, the annual meeting of the European Hematology Association taking place in Frankfurt, Germany on June 8-11, 2023.

• Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology (ASCO)

  4/26/2023

  Affimed N.V. announced that two abstracts with its innate cell engager AFM24 have been accepted for the American Society of Clinical Oncology Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL.

• 

  AACR Weekend Roundup: Roche, AstraZeneca, Moderna, Merck and Affimed

  4/17/2023

  Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.

• Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the AACR Annual Meeting 2023

  4/16/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, provided the final results from its phase 2 REDIRECT study investigating its innate cell engager AFM13 monotherapy in patients with heavily pretreated advanced-stage r/r PTCL.

• Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement - April 06, 2023

  4/6/2023

  Affimed N.V. announced that it has received a written notice, dated April 4, 2023, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, for the last thirty consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550.

• Affimed Announces First Patient Successfully Dosed in the First-in-Human Study of AFM28 for the Treatment of Patients with Relapsed / Refractory CD123-Positive Acute Myeloid Leukemia

  3/29/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that the first patient was dosed in a phase 1 multicenter, open label, first-in-human dose escalation study of the innate cell engager AFM28 monotherapy in patients with CD123-positive relapsed/refractory acute myeloid leukemia.

• Affimed Reports 2022 Financial Results and Operational Progress

  3/23/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.

• Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023

  3/16/2023

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release full year 2022 results and corporate update on Thursday, March 23, 2023.

• Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the AACR

  3/14/2023

  Affimed N.V. announced that two abstracts with clinical and preclinical data on AFM13, its anti-CD30 targeting innate cell engager, have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research, taking place April 14-19, 2022 in Orlando, Florida.

• Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

  1/9/2023

  Affimed N.V. announced that the U.S. Food and Drug Administration has issued a written response to the Company’s pre-IND meeting request for the AFM13 and Artiva Biotherapeutics, Inc. ’s AB-101 co-administered combination therapy in relapsed/refractory Hodgkin lymphoma and the exploratory arm evaluating the combination in r/r CD30-positive peripheral T-cell lymphoma.

• 

  Affimed Redirects Focus to NK Combo in Rare Type of Lymphoma

  12/12/2022

  Affimed will not seek accelerated approval for AFM13 as a monotherapy in advanced-stage relapsed/refractory peripheral T cell lymphoma.

• Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

  12/10/2022

  Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced topline data from its phase 2 REDIRECT study investigating AFM13 monotherapy in patients with advanced-stage r/r PTCL.